Hepatitis E: What’s New?
HEV Diagnosis Acute HEV Chronic HEV Immuno competent Immuno compromised HEV-RNA in serum IgM anti-HEV HEV-RNA Baylis SA, et al. J Clin Microbiol 2011; 49:1234. Khudyakov Y, Kamili S. Virus Res 2011; 161:84. HEV-RNA in serum IgG anti-HEV Ab marker of exposure titers decline with time
Treatment of HEV Immune Status Stage of disease Acute HEV • Supportive treatment. • Fulminant hepatic failure require LTx. • RBV monotherapy in CLD patients & those on IS therapy or chemotherapy. • ??Improvement: spontaneous or due to RBV. Dalton HR, et al. Nat Rev Neurol 2016; 12:77. Del Bello A, et al. Transpl Infect Dis 2015; 17:279. Blasco-Perrin H, et al. Aliment Pharmacol Ther 2015; 42:574.
- Page 2 and 3: HEPATITIS E: WHAT’S NEW? Naglaa Z
- Page 4 and 5: Known Facts: HEV ■ 20 million HEV
- Page 6 and 7: Geographical Distribution of HEV Eg
- Page 8 and 9: HEV Genotypes Four genotypes/24 sub
- Page 10 and 11: Modes of HEV Transmission Fecal-ora
- Page 12 and 13: Clinical Picture of HEV
- Page 14 and 15: Complications of Acute HEV Acute Li
- Page 16 and 17: Clinical Picture: Complications Acu
- Page 18 and 19: Chronic Hepatitis E Persistently el
- Page 20 and 21: Chronic Hepatitis E Other Immunosup
- Page 22 and 23: Diagnostic tests for HEV IgM anti-H
- Page 26 and 27: Treatment of HEV Acute HEV Signific
- Page 28 and 29: Treatment of Chronic HEV Reduction
- Page 30 and 31: Response to Antiviral Therapy Stool
- Page 34 and 35: Treatment of HEV: Future Therapy
- Page 36 and 37: Randomized trial in China, 112,604
HEV Diagnosis<br />
Acute HEV<br />
Chronic HEV<br />
Immuno<br />
competent<br />
Immuno<br />
compromised<br />
HEV-RNA in serum<br />
IgM anti-HEV<br />
HEV-RNA<br />
Baylis SA, et al. J Clin Microbiol 2011; 49:1234.<br />
Khudyakov Y, Kamili S. Virus Res 2011; 161:84.<br />
HEV-RNA in<br />
serum<br />
IgG anti-HEV Ab<br />
marker of exposure<br />
titers decline with time
Change language